Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Capital Leases (2018)

Regenxbio has reported Capital Leases over the past 1 years, most recently at $5.9 million for Q4 2018.

  • Quarterly results put Capital Leases at $5.9 million for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was $5.9 million (changed N/A YoY), and the annual figure for FY2018 was $5.9 million, changed.
  • Capital Leases for Q4 2018 was $5.9 million at Regenxbio.
  • Over the last five years, Capital Leases for RGNX hit a ceiling of $5.9 million in Q4 2018 and a floor of $5.9 million in Q4 2018.